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Abstract	  
The	  ATP	  Binding	  Cassette	  transporter	  ABCB1	  can	  export	  the	  neurotoxic	  peptide	  β-­‐amyloid	  from	  
endothelial	  cells	  that	  line	  the	  blood-­‐brain	  barrier	  (BBB).	  This	  has	  the	  potential	  to	  lower	  cerebral	  
levels	   of	   β-­‐amyloid,	   but	  ABCB1	   expression	   in	   the	  BBB	  appears	   to	   be	  progressively	   reduced	   in	  
patients	  with	  Alzheimer’s	  disease.	  The	  surface	  density	  of	  many	  membrane	  proteins	  is	  regulated	  
by	  ubiquitination	  catalysed	  by	  ubiquitin	  E3	  ligases.	  In	  brain	  capillaries	  of	  mice	  challenged	  with	  
β-­‐amyloid	  ex	  vivo,	  we	   show	   that	   the	   level	  of	   the	  ubiquitin	   ligase	  Nedd4	   increases	   concomitant	  
with	  reduction	  in	  Abcb1.	  In	  vitro	  we	  show	  that	  human	  ABCB1	  is	  a	  substrate	  for	  human	  NEDD4-­‐1	  
ligase.	  Recombinant	  ABCB1	  was	  purified	  from	  Sf21	  insect	  cells	  and	  incubated	  with	  recombinant	  
NEDD4-­‐1	  purified	  from	  E.	  coli.	  The	  treated	  ABCB1	  had	  reduced	  mobility	  on	  SDS-­‐PAGE,	  and	  mass	  
spectrometry	   identified	  eight	   lysine	   residues,	  K271,	  K272,	  K575,	  K685,	  K877,	  K885,	  K887	  and	  
K1062	  that	  were	  ubiquitinated	  by	  NEDD4-­‐1.	  Molecular	  modelling	  showed	  that	  all	  of	  the	  residues	  
are	   exposed	   on	   the	   surface	   of	   the	   intracellular	   domains	   of	   ABCB1.	   K877,	   K885	   and	   K887	   in	  
particular,	   are	   located	   in	   the	   intracellular	   loop	   of	   transmembrane	   helix	   10	   (TMH10)	   in	   close	  
proximity,	   in	   the	   tertiary	   fold,	   to	   a	   putative	   NEDD4-­‐1	   binding	   site	   in	   the	   intracellular	   helix	  
extending	   from	   TMH12	   (PxY	   motif,	   residues	   996-­‐998).	   Transient	   expression	   of	   NEDD4-­‐1	   in	  
HEK293	  Flp-­‐In	   cells	   stably	   expressing	  ABCB1	  was	   shown	   to	   reduce	   the	   surface	  density	   of	   the	  
transporter.	  Together,	  the	  data	  identify	  this	  ubiquitin	  ligase	  as	  a	  potential	  target	  for	  intervention	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Introduction	  	  
Alzheimer’s	  disease	  is	  characterised	  by	  the	  accumulation	  of	  β-­‐amyloid	  within	  the	  brain.	  Reduced	  
clearance	   of	   β-­‐amyloid	   across	   the	   blood-­‐brain	   barrier	   (BBB)	   is	   a	   contributory	   factor	   in	   this	  
pathophysiology	  (Cirrito	  et	  al.	  2005;	  Kuhnke	  et	  al.	  2007;	  Zlokovic,	  2008).	  Transcellular	  clearance	  
across	   the	   endothelial	   cells	   of	   the	   BBB	   is	   thought	   to	   be	   a	   two-­‐step	   process;	   at	   the	   abluminal	  
membrane,	  the	  receptor	  LRP1	  has	  been	  implicated	  in	  β-­‐amyloid	  uptake	  from	  the	  cerebrospinal	  
fluid	  (Deane	  et	  al.	  2004),	  while	  at	  the	  luminal	  membrane,	  transport	  into	  the	  blood	  is	  mediated	  by	  
the	   ATP	   Binding	   Cassette	   transporter,	   ABCB1	   (also	   known	   as	   P-­‐glycoprotein	   or	   MDR1)	  
(Vogelgesang	   et	   al.	   2002;	   Cirrito	   et	   al.	   2005;	   Hartz	   et	   al.	   2010).	   In	   patients	   with	   Alzheimer’s	  
disease	   the	   level	   of	   ABCB1	   expression	   and	   deposition	   of	   β-­‐amyloid	   in	   the	   brain	   are	   inversely	  
correlated,	   suggesting	   that	   progressive	   loss	   of	   ABCB1	   expression	   allows	   β-­‐amyloid	   to	  
accumulate	  (Vogelgesang	  et	  al.	  2002;	  Jeynes	  and	  Provias,	  2011).	  This	  correlate	  is	  also	  true	  of	  the	  
mouse	   model	   of	   Alzheimer’s	   disease	   that	   overexpresses	   human	   amyloid	   precursor	   protein	  
(hAPP)	   (Cirrito	  et	  al.	  2005;	  Karlnoski	  et	  al.	  2009).	   In	   resected	  brain	  capillaries	   from	  wild	   type	  
mice,	  Abcb1	  expression	  is	  reduced	  on	  challenge	  with	  the	  hAPP	  proteolytic	  fragment	  Aβ40	  (Hartz	  
et	  al.	  2010).	  In	  the	  same	  study	  it	  was	  also	  shown	  that	  up-­‐regulation	  of	  Abcb1	  levels	  by	  activation	  
of	  the	  PXR	  transcription	  factor	  can	  maintain	  Abcb1	  levels,	  restore	  efflux	  and	  protect	  against	  β-­‐
amyloid	  accumulation	  in	  the	  brain.	  	  
The	  mechanism	  by	  which	  ABCB1	  is	  lost	  from	  the	  BBB	  (with	  age	  and	  on	  challenge	  by	  
Aβ40)	  is	  not	  known,	  but	  is	  likely	  to	  involve	  internalisation	  of	  the	  transporter	  from	  the	  abluminal	  
membrane.	   Internalisation	   of	   proteins	   from	   the	   cell	   surface	   is	   commonly	   regulated	   by	   post-­‐
translational	   modification	   with	   ubiquitin,	   a	   76	   amino	   acid	   polypeptide	   that	   is	   attached	  
covalently	   to	   lysine	   residues	   in	   the	   target	   protein.	   Ubiquitination	   requires	   the	   sequential	  
activation	  of	  three	  enzymes:	  a	  ubiquitin-­‐activating	  enzyme	  (E1),	  a	  ubiquitin-­‐conjugating	  enzyme	  
(E2),	   and	   a	   ubiquitin	   ligase	   (E3).	   Of	   these,	   it	   is	   the	   ubiquitin	   ligase	   that	   typically	   imparts	  
specificity	  for	  the	  target	  protein	  and	  catalyses	  the	  transfer	  of	  ubiquitin.	  NEDD4-­‐1	  is	  an	  ubiquitin	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E3	  ligase	  that	  is	  expressed	  in	  many	  tissues.	  It	  comprises	  an	  amino	  terminal	  C2	  domain,	  four	  WW	  
domains	  and	  a	  carboxy-­‐terminal	  HECT	  domain.	  The	  C2	  domain	  binds	  membrane	  phospholipids	  
which	   localises	  NEDD4-­‐1	   to	   the	   periphery	   of	   cells	   in	  which	   it	   is	   expressed	   (Anan	   et	   al.	   1998;	  
Ingham	   et	   al.	   2004).	   The	   class	   I,	   WW	   domains	   (named	   for	   the	   presence	   of	   pairs	   of	   highly	  
conserved	  tryptophan	  residues	  20-­‐22	  amino	  acids	  apart)	  bind	  to	  PxY	  motifs	  in	  the	  target	  protein	  
although	  these	  ligases	  can	  also	  target	  proteins	  indirectly	  through	  an	  adaptor	  protein	  (Sudol	  et	  al.	  
1995;	  Sudol	  and	  Hunter,	  2000),	  and	   the	  HECT	  domain	  catalyses	   the	   transfer	  of	  ubiquitin	   from	  
the	  activated	  E3	  ligase	  to	  the	  target	  protein	  (Rotin	  and	  Kumar,	  2009).	  	  
In	  the	  current	  study,	  we	  test	  the	  hypothesis	  that	  human	  ABCB1	  is	  a	  substrate	  for	  the	  
NEDD4-­‐1	   ubiquitin	   ligase	   and	   also	   examine	   its	  effect	   on	   surface	   density	   of	   ABCB1	   in	   cultured	  
cells.	   The	   data	   suggest	   that	   the	   level	   of	   ABCB1	   protein	   in	   the	   Alzheimer	   brain	   is	   subject	   to	  
ubiquitin-­‐mediated	  internalisation	  catalysed	  by	  a	  member	  of	  the	  NEDD4	  family	  	  
Methods	  	  
Materials.	  Dulbecco’s	  modified	   eagle	  medium	   (DMEM),	  DMEM/F-­‐12,	   fetal	   bovine	   serum	   (FBS),	  
phosphate	   buffered	   saline	   (PBS)	   and	   Sf-­‐900™	   II	   SFM	   medium	   were	   purchased	   from	   Life	  
Technologies	   (Paisley,	   UK).	   n-­‐Dodecyl-­‐β-­‐D-­‐maltoside	   was	   purchased	   from	   Merck	   Serono	  
(Feltham,	   UK).	   Lipids	   were	   purchased	   from	   Avanti	   Polar	   Lipids	   (Alabaster,	   AL	   USA).	   Ni-­‐NTA	  
agarose	   was	   from	   Qiagen	   (Manchester,	   UK).	   Plasmid	   pBacPAK9	   was	   from	   Clontech	   (Saint-­‐
Germain-­‐en-­‐Laye,	   France)	   and	   pcDNA5/FRT	   and	   pIZ-­‐V5His	   were	   from	   Life	   Technologies	  
(Paisley,	  UK).	  The	  baculoviral	  genome	  of	  ProFold™-­‐ER1	  was	  sourced	  from	  AB	  vector	  (San	  Diego,	  
CA	  USA).	   Flp-­‐In™	  293	   cells	  were	   purchased	   from	  Life	   Technologies	   (Paisley,	   UK).	  Mouse	   anti-­‐
ABCB1	   antibodies	   C219	   and	   4E3	  were	   from	   Cambridge	   Bioscience	   (Cambridge,	   UK)	   and	   AbD	  
Serotec	  (Oxford,	  UK),	  respectively.	  HRP-­‐conjugated	  and	  R-­‐phycoerythrin-­‐conjugated	  AF488	  anti-­‐
mouse	   secondary	   antibodies	   were	   from	   Dako	   (Ely,	   UK).	   Antibodies	   against	   Nedd4	  
(corresponding	  to	  the	  WW2	  domain,	  amino	  acids	  395-­‐462	  of	  rat	  Nedd4)	  and	  β-­‐actin	  were	  from	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Abcam	   (Cambridge,	  MA,	  USA).	  Human	  Aβ40	   and	   all	   other	   chemicals	  were	   from	  Sigma-­‐Aldrich	  
(Poole,	  UK	  or	  St.	  Louis,	  MO,	  USA).	  
Animals.	   All	   animal	   protocols	   were	   approved	   by	   the	   Institutional	   Animal	   Care	   and	   Use	  
Committees	   (IACUC)	   of	   the	  University	   of	  Minnesota	   (IACUC	  protocol	  #1110A05865;	   PI:	   Anika	  
M.S.	  Hartz)	  and	  carried	  out	  in	  strict	  accordance	  with	  AAALAC	  regulations,	  the	  US	  Department	  of	  
Agriculture	  Animal	  Welfare	  Act,	  and	  the	  Guide	  for	  the	  Care	  and	  Use	  of	  Laboratory	  Animals	  of	  the	  
NIH.	  Male	   transgenic	  mice	   overexpressing	   human	   amyloid	   precursor	   protein	   (hAPP)	   [Tg2576	  
strain;	   129S6.Cg-­‐Tg(APPSWE)2576Kha]	   and	   corresponding	   wild-­‐type	   mice	   were	   purchased	  
from	   Taconic	   Farms	   (Germantown,	   NY,	   USA).	   All	   mice	   were	   single-­‐housed	   and	   kept	   under	  
controlled	  environmental	  conditions	  (23°C,	  35%	  relative	  humidity;	  12-­‐hour	  light/dark	  cycle).	  	  
Isolation	  of	  capillaries	  from	  mouse	  brain.	  Brain	  capillaries	  were	  isolated	  as	  described	  previously	  
(Hartz	   et	   al.	   2010).	   Mice	   were	   euthanized	   by	   CO2	   inhalation	   and	   decapitated.	   Brains	   were	  
removed,	   dissected,	   and	   homogenized	   in	   ice	   cold	   PBS	   buffer	   (2.7	  mM	   KCl,	   1.46	  mM	   KH2PO4,	  
136.9	  mM	   NaCl,	   and	   8.1	  mM	   Na2HPO4	   supplemented	   with	   5	  mM	   D-­‐glucose	   and	   1	  mM	   sodium	  
pyruvate,	  pH	  7.4).	  Ficoll®	  was	  added	  to	  the	  minced	  brain	  to	  a	  final	  concentration	  of	  15%	  and	  the	  
Ficoll®/brain	   homogenate	   mixture	   was	   centrifuged	   at	   5800g	   for	   20	  min	   at	   4˚C.	   The	   capillary	  
pellet	  was	  resuspended	  in	  1%	  BSA,	  and	  the	  capillary	  suspension	  was	  passed	  over	  a	  glass	  bead	  
column.	  Brain	   capillaries	  adhering	   to	   the	  glass	  beads	  were	   collected	  by	  gentle	  agitation	   in	  1%	  
BSA.	  Brain	  capillaries	  were	  washed	  with	  BSA-­‐free	  PBS	  and	  used	  for	  experiments.	  
Western	   blotting.	   Protein	   expression	   levels	   in	   brain	   capillaries	   were	   analyzed	   by	   western	  
blotting	  as	  described	  previously	  (Hartz	  et	  al.	  2010).	  Brain	  capillaries	  were	  homogenized	  in	  lysis	  
buffer	  (Sigma,	  St.	  Louis,	  MO,	  USA)	  containing	  Complete®	  protease	   inhibitor	  (Roche,	  Mannheim,	  
Germany).	   Homogenized	   samples	   were	   centrifuged	   at	   10	   000g	   for	   15	  min	   at	   4°C	   and	  
denucleated	   supernatants	   were	   centrifuged	   at	   100	   000g	   for	   90	  min	   at	   4°C	   to	   obtain	   brain	  
capillary	   membranes.	   Brain	   capillary	   membranes	   were	   resuspendend	   in	   buffer	   containing	  
protease	   inhibitors	   and	   stored	   at	   -­‐80°C.	   Western	   blots	   were	   performed	   using	   the	   Invitrogen	  
NuPage™	   Bis-­‐Tris	   electrophoresis	   and	   blotting	   system	   (Invitrogen,	   Carlsbad,	   CA).	   After	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electrophoresis	   and	   protein	   transfer,	  membranes	  were	   blocked	   and	   incubated	   overnight	  with	  
the	   primary	   antibody	   indicated.	   Membranes	   were	   washed	   and	   incubated	   with	   horseradish	  
peroxidase-­‐conjugated	  ImmunoPure	  secondary	  IgG	  (1:15	  000;	  Pierce,	  Rockford,	  IL,	  USA)	  for	  1	  h.	  
Proteins	   were	   detected	   using	   SuperSignal	   West	   Pico	   Chemoluminescent	   Substrate	   (Pierce,	  
Rockford,	   IL,	   USA)	   and	   visualized	   using	   a	   BioRad	   Gel	   Doc	   2000™	   gel	   documentation	   system	  
(BioRad,	   Hercules,	   CA,	   USA).	   QuantityOne	   1-­‐D	   software	   (version	   4.6.9;	   Bio-­‐Rad	   Laboratories)	  
was	   used	   for	   densitometric	   analysis	   of	   band	   intensities.	   Data	  were	   normalized	   to	   β-­‐actin	   and	  
presented	   as	  means	   ±	   SEM.	   To	   evaluate	   differences	   between	   controls	   and	   treated	   groups,	   the	  
data	   were	   analyzed	   by	   two-­‐tailed	   unpaired	   Student’s	   t-­‐test	   using	   Microsoft	   Excel™	   2010.	  
Differences	  were	  considered	  to	  be	  statistically	  significant	  at	  P	  <	  0.05.	  
Plasmid,	  baculoviral	  vectors	  and	  cell	  lines.	  The	  human	  ABCB1-­‐6His	  cDNA	  (described	  previously	  in	  
Taylor	  et	  al.	  (Taylor	  et	  al.	  2001))	  was	  modified	  by	  site-­‐directed	  mutagenesis	  to	  introduce	  an	  AgeI	  
restriction	  site	  in	  place	  of	  the	  translational-­‐stop	  codon	  and	  subcloned	  into	  the	  vector	  pIZ-­‐V5His	  
to	  encode	  a	  12-­‐histidine	  carboxy-­‐terminal	  tag.	  The	  ABCB1-­‐12His	  cDNA	  was	  then	  subcloned	  into	  
the	   pBacPAK9	   baculoviral	   transfer	   vector	   to	   generate	   pBacPAK9-­‐ABCB1-­‐12His.	   The	   full	   cDNA	  
was	  sequenced	  and	  the	  carboxy-­‐terminus	  of	  the	  recombinant	  transporter	  confirmed	  as	  ABCB1-­‐
1277TKRQ-­‐GHHHHHHTGHHHHHH1295.	   pcDNA3-­‐NEDD4-­‐1-­‐mCherry	  was	   constructed	  using	   a	   full-­‐
length	  human	  NEDD4-­‐1	  IMAGE	  clone	  (clone	  8862584,	  Source	  Bioscience)	  inserted	  into	  pcDNA3	  
with	  mCherry	   as	   an	   N-­‐terminal	   fusion.	   Sf21	   insect	   cells	   were	   co-­‐transfected	   with	   pBacPAK9-­‐
ABCB1-­‐12His	   and	   ProFold™-­‐ER1	   to	   generate	   the	   baculovirus	   ProFold-­‐ABCB1-­‐12His	   by	  
homologous	   recombination	   in	   the	   cultured	   cells,	   as	   described	  by	   the	   supplier	   (AB	   vector;	   San	  
Diego,	  CA,	  USA).	  The	  ABCB1-­‐12His	  cDNA	  was	  subcloned	  into	  the	  pcDNA5/FRT	  vector	  to	  generate	  
pcDNA5/FRT-­‐ABCB1-­‐12His.	  Flp-­‐In™	  293	  cells	  (Life	  Technologies,	  Paisley,	  UK)	  were	  transfected	  
with	   pcDNA5/FRT-­‐ABCB1-­‐12His.	   Transfectants	   were	   selected	   for	   hygromycin	   resistance	   and	  
colonies	  cloned	  to	  generate	  a	  stable	  Flp-­‐In-­‐ABCB1-­‐12His	  cell	  line.	  
Insect	   cell	   culture.	   Sf21	   insect	   cells	   were	   cultured	   in	   suspension	   in	   Sf-­‐900™	   II	   SFM	   medium	  
supplemented	   with	   penicillin	   G	   and	   streptomycin.	   Cultures	   were	   maintained	   at	   27°C	   in	   an	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orbital	  shaker	  at	  120	  rpm.	  Sf21	  cells	  infected	  with	  ProFold-­‐ABCB1-­‐12His	  were	  cultured	  for	  72	  h	  
prior	  to	  harvesting	  by	  centrifugation.	  
Mammalian	   cell	   culture.	   Flp-­‐In-­‐ABCB1-­‐12His	   cells	  were	   grown	   as	   a	  monolayer	   in	   DMEM	  with	  
Glutamax™,	  supplemented	  with	  10%	  FBS	  and	  incubated	  in	  5%	  CO₂	  in	  a	  humidified	  incubator	  at	  
37°C.	  Maintenance	  of	   the	   integrated	  plasmid	  DNA	  was	  ensured	  by	  culturing	   in	   the	  presence	  of	  
100	  µg/ml	  hygromycin	  B.	  	  
Purification	  of	  ABCB1.	  Crude	  membrane	  fractions	  were	  prepared	  from	  infected	  Sf21	  insect	  cells	  
as	   described	   previously	   (Martin	   et	   al.	   2007).	   ABCB1	   was	   solubilised	   in	   mixed	   micelles	   of	   n-­‐
dodecyl-­‐β-­‐D-­‐maltoside	  and	  E.	  coli	  lipids	  supplemented	  with	  cholesterol,	  and	  purified	  by	  Ni-­‐NTA	  
affinity	   chromatography	   by	   virtue	   of	   the	   engineered	   carboxy-­‐terminal	   12	   x	   histidine	   tag,	  
essentially	  as	  described	  previously	  (Ritchie	  et	  al.	  2009),	  with	  the	  following	  modifications.	  Initial	  
binding	  to	  the	  resin	  was	  performed	  in	  the	  presence	  of	  10mM	  imidazole.	  The	  resin	  was	  washed	  
four	   times	   with	   20	   bed	   volumes	   of	   wash	   buffer	   containing	   incremental	   concentrations	   of	  
imidazole	   (40	   mM,	   80	   mM,	   100	   mM,	   120	   mM),	   and	   eluted	   with	   500	   mM	   imidazole.	   Buffer	  
exchange	  to	  remove	  the	  imidazole	  was	  achieved	  by	  multiple	  concentration/dilution	  cycles	  using	  
an	   Amicon®	   Ultra-­‐4	   Centrifugal	   Filter	   Unit	   (100	   kDa	   cut	   off;	   Merck	   Millipore,	   DE,	   USA).	  
Purification	  was	  monitored	  by	  SDS-­‐PAGE.	  Proteins	  were	  separated	  on	  a	  7.5%	  resolving	  gel	  and	  
stained	  with	  colloidal	  blue.	  	  
Purification	  of	  NEDD4-­‐1.	  GST-­‐tagged	  human	  ubiquitin	   ligase	  NEDD4-­‐1	  was	   expressed	   in	  E.	  coli	  
and	   purified	   by	   glutathione	   affinity	   chromatography,	   as	   described	   previously	   (Sullivan	   et	   al.	  
2007).	  
Ubiquitination	  reaction.	   Purified	  ABCB1	   (20	   μg	   in	   50	   μl	   final	   volume)	  was	  mixed	  with	   5	   μg	   of	  
methylated	   ubiquitin	   (to	   limit	   modification	   to	   mono-­‐ubiquitination),	   100	   ng	   of	   ubiquitin-­‐
activating	  enzyme	  (E1;	  Boston	  Biochem,	  MA,	  USA),	  100	  ng	  of	  Ubc1	  ubiquitin-­‐conjugating	  enzyme	  
(E2)	   (Sullivan	  et	  al.	  2007)	  and	  20	  μl	  of	  NEDD4-­‐1	  at	  a	  concentration	  of	  500	  ng/μl	   in	  a	  reaction	  
solution	  of	  50	  mM	  Tris	  pH	  7.4,	  10	  mM	  ATP,	  10	  mM	  MgCl₂	  and	  incubated	  at	  37°C	  for	  2	  hours.	  In	  a	  
control	   sample,	   methylated	   ubiquitin	   was	   omitted.	   The	   reaction	   was	   stopped	   after	   2	   h	   by	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addition	  of	  50	  µl	  of	  SDS	  sample	  loading	  buffer.	  The	  sample	  was	  electrophoresed	  through	  an	  8%	  
Precise™	   tris-­‐glycine	   gel	   (Thermo	   Fisher	   Scientific,	   UK),	   blotted	   and	   ABCB1	   detected	   with	  
antibody,	  C219.	  	  
Mass	  Spectrometry.	  ABCB1	  was	  excised	  from	  the	  tris-­‐glycine	  gel	  and	  digested	  using	  trypsin.	  The	  
tryptic	   fragments	   were	   dissolved	   in	   0.1%	   formic	   acid	   and	   separated	   by	   reverse-­‐phase	   liquid	  
chromatography.	  Electrospray	  mass	  spectrometry	  was	  carried	  out	  on	  a	  LTQ	  Orbitrap	  Velos	  ETD	  
mass	   spectrometer	   (Thermo	   Fisher	   Scientific)	   at	   Birmingham	   Science	   City	   Translational	  
Medicine	  facility.	  The	  data	  were	  analysed	  by	  SearchGUI	  (Vaudel	  et	  al.	  2011)	  and	  peptide-­‐shaker	  
(Barsnes	  et	  al.	  2011;	  Vaudel	  et	  al.	  2011).	  
Flow	  cytometry.	  Flp-­‐In-­‐ABCB1-­‐12His	  cells	  were	  transfected	  transiently	  with	  pcDNA3-­‐NEDD4-­‐1-­‐
mCherry	   as	   described	   previously	   (Dixon	   et	   al.	   2000).	   The	   transfected	   cells	   and	   a	   mock	  
transfected	   control	   population	   were	   harvested	   48	   h	   post	   transfection	   and	   washed	   with	  
DMEM/F12	   (Life	   Technologies,	   Paisley	   UK)	   supplemented	   with	   1%	   FBS.	   The	   live	   cells	   were	  
stained	  for	  surface	  ABCB1	  using	  saturating	  amounts	  of	  the	  ABCB1-­‐specific	  primary	  antibody	  4E3	  
and	   R-­‐phycoerythrin-­‐conjugated	   goat	   anti-­‐mouse	   AF488	   secondary	   antibodies,	   as	   described	  
previously	   (Zolnerciks	   et	   al.	   2007).	   Fluorescence	   data	   were	   acquired	   on	   a	   FACScan	   flow	  
cytometer	   (Becton	  Dickinson),	  gating	   for	  10,000	  cells	  of	  normal	   size	  and	  granularity.	  mCherry	  
fluorescence	  was	  detected	   in	  FL-­‐2	   channel	   and	  AF488	  was	  detected	   in	   the	  FL-­‐1	   channel.	  Data	  





Challenge	   with	   Aβ40	   increases	   Nedd4	   and	   reduces	   Abcb1	   expression	   in	   the	   BBB	   of	   mice.	   Intact	  
brain	   capillaries	   were	   isolated	   from	   the	   brains	   of	   3-­‐month	   old	  wild-­‐type	   and	   hAPP	  mice	   and	  
analysed	  for	  Abcb1	  and	  Nedd4-­‐family	  ubiquitin	  ligase	  expression.	  Western	  analysis	  of	  capillary	  
membranes	   showed	   the	   presence	   of	   Nedd4	   in	  wild-­‐type	  mice	   (Figure	   1A).	   In	   capillaries	   from	  
hAPP	   mice	   Nedd4	   protein	   expression	   was	   increased	   by	   32%	   ±	   9.8	   (P	   <	   0.03;	   n=3)	   after	  
normalization	   to	  β-­‐actin	   levels.	  Exposing	   isolated	  capillaries	   from	  wild-­‐type	  animals	   to	  human	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Aβ40	  also	  increased	  Nedd4	  protein	  expression	  by	  42%	  ±	  5.7	  (P	  <	  0.002;	  n=3)	  compared	  to	  the	  
untreated	  control.	  The	  increase	  in	  Nedd4	  expression	  was	  concomitant	  with	  a	  reduction	  in	  Abcb1	  
levels	  by	  42%	  ±	  0.5	  (P	  <	  0.001;	  n=3)	  (Figure	  1B).	  These	  changes	  in	  the	  expression	  levels	  of	  the	  
two	   proteins	   were	   evident	   within	   six	   hours	   suggesting	   that	   Nedd4	   directly	   tags	   Abcb1	   with	  
ubiquitin	  to	  mediate	  Aβ-­‐mediated	  reduction	  of	  the	  transporter	  in	  Alzheimer’s	  disease.	  
	  
[insert	  Figure	  1	  near	  here]	  
	  
Human	  ABCB1	  is	  a	  substrate	  of	  NEDD4-­‐1.	  To	  test	  whether	  human	  ABCB1	  is	  a	  substrate	  for	  human	  
NEDD4-­‐1	  ubiquitin	   ligase	  we	  engineered	  a	  12	  x	  histidine	   tag	  onto	   the	  carboxy-­‐terminus	  of	   the	  
transporter.	   The	   recombinant	   transporter	   was	   expressed	   in	   insect	   cells,	   membranes	   were	  
fractionated,	   and	   the	   proteins	   solubilised	   using	   non-­‐denaturing	   n-­‐Dodecyl-­‐β-­‐D-­‐maltoside.	   The	  
solubilised	  recombinant	  ABCB1	  was	  purified	  by	  nickel-­‐affinity	  chromatography	  (Figure	  1C).	   In	  
the	  preparative	  purification	  the	  final	  wash	  included	  120	  mM	  imidazole	  (lane	  9),	  and	  the	  bound	  
ABCB1	   was	   eluted	   with	   500	   mM	   imidazole	   (equivalent	   to	   the	   combined	   lanes	   10	   –	   14).	   The	  
recovered	  protein	  was	  94%	  pure	  and	  we	  have	  shown	  previously	  that	  it	  can	  be	  reconstituted	  into	  
liposomes	   to	   regain	   drug-­‐stimulated	   ATPase	   activity	   thus	   the	   native	   fold	   is	   preserved	   in	   n-­‐
dodecyl-­‐β-­‐D-­‐maltoside	   (Ritchie	   et	   al.	   2009).	   However,	   for	   the	   current	   purpose,	   the	   purified	  
protein	   was	   buffer	   exchanged	   to	   remove	   the	   imidazole	   and	   incubated	   with	   NEDD4-­‐1	   in	   a	  
reaction	  mixture	   that	  also	  contained	  ubiquitin	  E1	  and	  E2	  enzymes	  and	  recombinant	  ubiquitin.	  
The	  mobility	  of	  the	  treated	  ABCB1	  protein,	  but	  not	  the	  control	  sample	  from	  which	  ubiquitin	  was	  
omitted,	  was	  retarded	  on	  SDS-­‐PAGE	  suggesting	  that	  the	  treated	  ABCB1	  is	  modified	  directly	  with	  
ubiquitin	  and	  that	  NEDD4-­‐1	  recognises	  ABCB1	  as	  a	  substrate	  (Figure	  1D).	  	  
	  
[insert	  Table	  1	  near	  here]	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Identification	   of	   the	   ubiquitination	   sites.	   Treated	   and	   untreated	   ABCB1	   were	   excised	   from	   a	  
polyacrylamide	  gel	  and	  analysed	  by	  linear	  ion	  trap	  quadrupole	  with	  orbitrap	  mass	  spectrometry.	  
The	   data	   confirmed	   the	   purification	   of	   ABCB1	   and	   covered	   82%	   of	   the	   protein	   sequence.	  
Fragments	  and	  individual	  amino	  acids	  missing	  from	  the	  analysis	  covered	  amino	  acids	  114-­‐136,	  
I147,	  211-­‐231,	  292-­‐329,	  405-­‐416,	  460-­‐467,	  544-­‐547,	  579-­‐580,	  K681,	  703-­‐734,	  833-­‐864,	  K888,	  
1015-­‐1047,	  1184-­‐1192	  and	  1221-­‐1222.	  Eight	   lysine	   residues	   (K271,	  K272,	  K575,	  K685,	  K877,	  
K885,	   K887,	   K1062)	   were	   found	   to	   be	   ubiquitinated	   specifically	   in	   the	   sample	   treated	   with	  
NEDD4-­‐1	   (Table	   1).	   The	  positions	   of	   seven	  of	   the	   eight	  modified	   lysines	  were	  mapped	  onto	   a	  
homology	  model	   of	   the	   closed	   conformation	   of	   the	   transporter	   based	   largely	   on	   the	   Sav1866	  
crystal	   structure	   from	   S.	   aureus	   (Zolnerciks	   et	   al.	   2014),	   and	   also	   on	   the	   open	   conformation	  
described	  by	   the	  model	  of	  Abcb1a	   from	  M.	  musculus	   (in	  which	  all	   eight	   lysines	  are	   conserved;	  
(Aller	   et	   al.	   2009)).	   K685	   could	   not	   be	   modelled	   because	   it	   is	   in	   the	   linker	   region	   of	   ABCB1	  
between	   nucleotide-­‐binding	   domain	   1	   (NBD1)	   and	   transmembrane	   domain	   2	   (TMD2).	   This	  
region	  was	  not	  resolved	  in	  the	  Abcb1a	  crystal	  structure	  and	  is	  absent	  from	  Sav1866	  (Sav1866	  is	  
a	  half	  transporter	  with	  one	  TMD	  and	  one	  NBD	  which	  functions	  as	  a	  homodimer,	  whereas	  ABCB1	  
is	   a	   four-­‐domain	   polypeptide).	   All	   of	   the	   seven	   lysines	   mapped	   are	   located	   on	   the	   exposed	  
surface	   of	   the	   cytosolic	  moiety	   and	   are	   largely	   on	   the	   same	   face	   of	   the	   transporter	   (Figure	   2,	  
green	   spheres).	   Three	   of	   the	   lysine	   residues,	   K877,	   K885	   and	   K887	   are	   located	   in	   the	  
intracellular	  loop	  extending	  from	  transmembrane	  helix	  10	  (TMH10)	  and	  in	  very	  close	  proximity	  
to	  a	  unique	  PxY	  motif	  (P996-­‐D997-­‐Y998)	  in	  the	  intracellular	  loop	  of	  TMH12	  which	  may	  function	  
as	  a	  binding	  site	  for	  NEDD4-­‐1	  (Figure	  2,	  magenta	  spheres).	  It	  is	  possible	  that	  all	  eight	  lysines	  are	  
accessible	  to	  NEDD4-­‐1	  docked	  at	  this	  binding	  site,	  because	  K685	  must	  also	  be	  on	  the	  same	  face,	  
close	  to	  the	  first	  resolved	  residue	  in	  the	  amino-­‐terminal	  region	  of	  TMD2	  indicated	  by	  the	  yellow	  
spheres	  on	  the	  blue	  domains	  in	  Figure	  2.	  	  
	  
[insert	  Figure	  2	  near	  here]	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NEDD4-­‐1	  expression	  decreases	  surface	  ABCB1	  levels.	  To	  investigate	  the	  effect	  of	  NEDD4-­‐1	  on	  the	  
surface	  density	  of	  ABCB1	  we	  generated	  a	   stable	   cell	   line	   in	  which	  a	   single	   copy	  of	   the	  ABCB1-­‐
12His	   cDNA	   under	   the	   control	   of	   the	   CMV	   promoter	   was	   inserted	   into	   the	   genome	   of	   Flp-­‐In	  
HEK293	   cells.	   The	   Flp-­‐In-­‐ABCB1-­‐12His	   cells	   express	   a	   uniform	   level	   of	   ABCB1	   allowing	   the	  
surface	   density	   of	   ABCB1	   to	   be	  measured	   and	   the	   effect	   of	   introduced	  NEDD4-­‐1	   to	   be	   tested.	  
Surface	   density	   of	   ABCB1	   was	   measured	   in	   live	   cells	   by	   flow	   cytometry	   after	   staining	   with	  
saturating	   concentrations	   of	   anti-­‐ABCB1	   antibody	   (4E3)	   which	   recognises	   an	   extracellular	  
epitope	  of	  the	  transporter.	  Flp-­‐In-­‐ABCB1-­‐12His	  cells	  were	  transfected	  transiently	  with	  pcDNA3-­‐
NEDD4-­‐1-­‐mCherry,	   or	   mock	   transfected,	   and	   stained	   with	   4E3.	   Two-­‐colour	   flow	   cytometry	  
showed	  that	  the	  cherry-­‐coloured	  cells	  that	  express	  NEDD4-­‐1	  had	  less	  ABCB1	  on	  the	  cell	  surface	  
(Figure	  3).	  
	  
[insert	  Figure	  3	  near	  here]	  
Discussion	  
Transgenic	  mice	  engineered	  to	  overexpress	  human	  amyloid	  precursor	  protein	  develop	  cognitive	  
impairment	  with	  age	  that	  correlates	  with	  the	  accumulation	  of	  Aβ40	  and	  Aβ42	  in	  the	  brain	  (Hsiao	  
et	  al.	  1996;	  Hartz	  et	  al.	  2010).	  ABCB1,	  a	  primary	  active,	  drug	  pump	  of	  the	  luminal	  membrane	  of	  
the	  BBB	  endothelium	  is	  an	  important	  component	  of	  the	  chemical	  barrier	  and	  has	  been	  shown	  to	  
efflux	  Aβ40	   and	  Aβ42	   into	   the	   blood	   stream.	   In	  mouse	  BBB	   capillaries	   ex	  vivo,	   challenge	  with	  
Aβ40	   significantly	   lowers	   the	   level	   of	   total	   Abcb1	  within	   a	   few	   hours	   (Hartz	   et	   al.	   2010).	  We	  
show	   here	   that	   ubiquitin	   ligases	   of	   the	  Nedd4	   family	   are	   also	   elevated	   in	   this	   tissue	   over	   the	  
same	   timeframe,	   implicating	   their	   involvement	   in	   ubiquitin-­‐mediated	   degradation	   of	   the	  
transporter.	   To	   test	   this	   further	   we	   purified	   recombinant	   human	   ABCB1	   and	   NEDD4-­‐1	   and	  
showed	  that	  the	  transporter	  is	  indeed	  a	  substrate	  for	  the	  ubiquitin	  ligase.	  Eight	  lysine	  residues	  
of	   ABCB1	  were	   ubiquitinated	   by	  NEDD4-­‐1	   and	   these	  mapped	   essentially	   onto	   one	   face	   of	   the	  
transporter.	   In	   particular,	   a	   cluster	   of	   lysines	   (K877,	   K885,	   K887	   and	   K685)	   are	   in	   close	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proximity	   to	   a	   PxY	   motif,	   which	   forms	   a	   kink	   in	   the	   intracellular	   α-­‐helix	   extending	   into	   the	  
cytosol	  from	  TMH12.	  We	  propose	  that	  this	  PxY	  motif	  is	  a	  likely	  binding	  site	  for	  the	  WW	  domains	  
of	   NEDD4-­‐1.	   The	   inverse	   correlation	   between	   the	   expression	   of	   the	   transporter	   and	   the	  
ubiquitin	  ligase	  was	  recapitulated	  in	  cell	  culture	  in	  which	  we	  showed	  that	  the	  density	  of	  human	  
ABCB1in	  the	  plasma	  membrane	  was	  reduced	  when	  NEDD4-­‐1	  was	  transiently-­‐expressed	  in	  Flp-­‐
In-­‐ABCB1-­‐12His	  cells.	  	  
The	   density	   of	   most,	   if	   not	   all,	   proteins	   in	   the	   plasma	   membrane	   likely	   involves	   a	  
combination	  of	   factors	   including	   synthesis	   (transcription	  and	   translation),	  maturation	   (folding	  
and	   post-­‐translational	   modification),	   trafficking	   to	   the	   membrane,	   recycling	   to	   and	   from	  
endosomal	   compartments,	   and	   degradation.	   Of	   most	   relevance	   to	   the	   current	   study	   is	   the	  
reported	   long	   half-­‐life	   of	   the	   ABCB1	   protein.	   Various	   studies	   in	   different	   cell	   types	   have	  
measured	  the	  half-­‐life	  of	  ABCB1	  and	  reported	  wide	  ranging	  values	  from	  72	  hours	  (Richert	  et	  al.	  
1988;	  Yoshimura	  et	  al.	  1989),	  24	  hours	  (Mickley	  et	  al.	  1989)	  to	  the	  shortest	  report	  of	  14	  to	  17	  
hours	  (Muller	  et	  al.	  1995).	  In	  comparison,	  the	  processing	  and	  trafficking	  of	  nascent	  ABCB1	  to	  the	  
plasma	  membrane	   is	   relatively	   fast	  with	   the	  nascent	  protein	   reported	   to	  have	  a	  half-­‐life	  of	  45	  
minutes	   on	   the	   pathway	   to	   maturity	   (Yoshimura	   et	   al.	   1989).	   If	   these	   characteristics	   also	  
describe	   ABCB1	   in	   BBB	   endothelial	   cells	   then	   the	   rapid	   reduction	   in	   ABCB1	   protein	   level	  
observed	  on	  challenge	  with	  Aβ40	  would	  require	  a	  significant	  lowering	  of	  the	  half-­‐life.	  The	  data	  
presented	  herein	  suggest	  the	  following	  mechanism	  as	  most	  likely;	  Aβ40	  induces	  the	  expression	  
and	  activation	  of	  NEDD4-­‐1,	  which	  binds	  to	  the	  PxY	  motif	  of	  ABCB1.	  The	  ligase	  ubiquitinates	  the	  
transporter	   thus	   tagging	   it	   for	   internalisation	   from	   the	   membrane	   and	   degradation.	   Integral	  
membrane	  proteins	   internalised	   from	   the	  plasma	  membrane	   are	  most	   commonly	  degraded	   in	  
the	   lysosome.	   This	   would	   be	   consistent	   with	   the	   reported	   co-­‐localisation	   of	   ABCB1	   and	   the	  
lysosomal	  marker	  LAMP-­‐2	  (Fu	  and	  Roufogalis,	  2007),	  however	  we	  cannot	  rule	  out	  at	  present	  a	  
proteasomal	  degradation	  pathway	  which	  has	  also	  been	  reported	  for	  ABCB1	  (Zhang	  et	  al.	  2004;	  
Katayama	  et	  al.	  2013).	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A	   number	   of	   questions	   remain	   to	   be	   addressed.	   For	   example,	   the	   mechanism	   of	  
induction	   and	   regulation	   of	   NEDD4-­‐family	   ligases	   in	   BBB	   endothelial	   cells,	   and	   whether	  
ubiquitination	  also	  inhibits	  the	  function	  of	  the	  transporter,	  remain	  unknown.	  Nevertheless,	  the	  
proposed	   mechanism	   fits	   well	   with	   the	   available	   data	   and	   suggests	   NEDD4-­‐family	   ubiquitin	  
ligases	   may	   present	   a	   therapeutic	   target	   to	   help	   retain	   ABCB1	   expression	   at	   the	   BBB	   in	  
Alzheimer	  brains,	  and	  mediate	  clearance	  of	  Aβ40	  and	  Aβ42	  from	  the	  brain	  compartment.	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Figure	   1.	   (A)	  Representative	  western	  analysis	  of	  protein	   lysates	  prepared	   from	   isolated	  brain	  
capillaries	  from	  matched	  wild-­‐type	  and	  hAPP	  mice	  at	  age	  3	  months,	  and	  (B)	  capillaries	  of	  wild-­‐
type	  mice	  before	  and	  after	  challenge	  with	  100nM	  human	  Aβ40.	  (C)	  Purification	  profile	  by	  metal	  
affinity	   chromatography	   of	   human	   ABCB1.	   Lanes	   1,	   membrane	   fraction	   (100μg	   of	   protein	   or	  
0.25%	  of	  volume);	  2,	  solubilised	  membrane	  fraction	  (0.25%);	  3,	  column	  flow-­‐through	  (0.25%);	  
4-­‐13,	  washes	  from	  20	  mM	  to	  200	  mM	  imidazole	  in	  20	  mM	  increments	  (each	  4%	  of	  volume);	  14,	  
EDTA	   50	   mM	   (4%	   of	   volume).	   (D)	   Western	   analysis	   of	   purified	   ABCB1	   before	   and	   after	  
ubiquitination.	   NEDD4-­‐1	   reaction	   mixture	   in	   the	   absence	   (lane	   1)	   and	   presence	   (lane	   2)	   of	  
methylated	  ubiquitin.	  	  
	  
Figure	  2.	   	  Cartoon	  representation	  of	  two	  conformations	  of	  ABCB1.	  (A)	  Homology	  model	  based	  
on	  Sav1866	  (pdb	  2HYD)	  from	  S.	  aureus.	  (B)	  Model	  of	  mouse	  Abcb1a	  (pbd	  35GU).	  In	  each	  case	  the	  
domains	   are	   coloured	   from	   the	   amino	   terminus	   as	   follows	   TMD1,	   red;	   NBD1,	   orange;	   TMD2,	  
blue;	  NBD2,	   cyan.	   The	   side	   chains	   of	   the	   putative	  NEDD4-­‐1	  binding	  motif	   (PxY)	   are	   shown	  as	  
magenta	  spheres	  (P996	  and	  Y998).	  The	  ubiquitinated	  lysines	  are	  shown	  as	  green	  spheres.	  The	  
linker	  region	  linking	  NBD1	  to	  TMD2	  could	  not	  be	  modelled	  in	  either	  conformation	  therefore	  the	  
precise	   position	   of	   K685	   is	   not	   known	   but	  must	   be	   close	   to	   the	   first	   resolved	   residue	   in	   the	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amino-­‐terminal	   region	   of	   TMD2,	   which	   in	   the	   closed	   conformation	   is	  W698,	   and	   in	   the	   open	  
conformation	  is	  equivalent	  to	  L688	  of	  human	  ABCB1.	  The	  C-­‐alphas	  of	  W698	  and	  the	  equivalent	  
of	  L688	  are	  shown	  as	  yellow	  spheres	  in	  the	  blue	  domain.	  	  
	  
Figure	   3.	   Flow	  cytometric	  analysis	  of	  ABCB1	   in	   the	  plasma	  membrane	  of	  Flp-­‐In-­‐ABCB1-­‐12His	  
cells.	  Left	  dotplot,	  cells	  were	  gated	  for	  normal	  size	  and	  granularity	  (the	  same	  gate	  was	  used	  for	  
populations);	  Middle	  dotplot,	   two	  colour	  analysis	  of	  mock-­‐transfected	  cells;	  Right	  dotplot,	   two	  
colour	   analysis	   of	   cells	   transfected	   transiently	   with	   pcDNA3-­‐NEDD4-­‐1-­‐mCherry.	   Each	   dot	  
represents	  a	  single	  cell	  and	  the	  density	  of	  cells	  is	  colour	  coded	  from	  blue	  (few	  cells)	  to	  red	  (many	  
cells).	  The	  numbers	   represent	   the	  percentage	  of	   cells	   in	   a	   given	  gate,	   and	   the	   coloured	   letters	  
define	  the	  analytical	  gates	  used	  to	  plot	  the	  histogram.	  The	  histogram	  shows	  ABCB1	  expression	  in	  
NEDD4-­‐1-­‐expressing	   (orange	   and	   red)	   and	   non-­‐expressing	   cells	   (blue	   and	   green).	   Histogram	  
colour	  coding	  is	  consistent	  with	  the	  lettering	  in	  the	  dotplots.	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